Goldman Sachs’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-10,765
| Closed | -$16.1K | – | 6241 |
|
|
2023
Q1 | $16.1K | Sell |
10,765
-956
| -8% | -$1.29K | ﹤0.01% | 5689 |
|
|
2022
Q4 | $11.7K | Sell |
11,721
-28,193
| -71% | -$38K | ﹤0.01% | 5739 |
|
|
2022
Q3 | $72K | Sell |
39,914
-43,552
| -52% | -$126K | ﹤0.01% | 5756 |
|
|
2022
Q2 | $242K | Sell |
83,466
-85,333
| -51% | -$211K | ﹤0.01% | 5547 |
|
|
2022
Q1 | $466K | Sell |
168,799
-173,965
| -51% | -$547K | ﹤0.01% | 5363 |
|
|
2021
Q4 | $1.6M | Buy |
342,764
+262,897
| +329% | +$1.64M | ﹤0.01% | 4437 |
|
|
2021
Q3 | $680K | Sell |
79,867
-240,070
| -75% | -$3.39M | ﹤0.01% | 5009 |
|
|
2021
Q2 | $5.25M | Sell |
319,937
-60,781
| -16% | -$1.23M | ﹤0.01% | 3293 |
|
|
2021
Q1 | $8.41M | Buy |
380,718
+132,700
| +54% | +$3.62M | ﹤0.01% | 2705 |
|
|
2020
Q4 | $7.67M | Buy |
248,018
+200,666
| +424% | +$5.07M | ﹤0.01% | 2668 |
|
|
2020
Q3 | $962K | Buy |
47,352
+30,684
| +184% | +$539K | ﹤0.01% | 4104 |
|
|
2020
Q2 | $256K | Buy |
+16,668
| New | +$192K | ﹤0.01% | 4694 |
|
|
2019
Q2 | – | Sell |
-56,443
| Closed | -$984K | – | 5416 |
|
|
2019
Q1 | $984K | Buy |
+56,443
| New | +$1M | ﹤0.01% | 4065 |
|
Goldman Sachs's TCRR Position: Q2 2023 in Review
Goldman Sachs sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 10,765 shares — an estimated $16.1K sold.
Goldman Sachs first reported a position in TCRR in Q1 2019 and held it in 13 quarters. The position peaked at $8.41M in Q1 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- Goldman Sachs reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Goldman Sachs sold 10,765 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $16.1K.
- Goldman Sachs first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 13 quarters.
- Goldman Sachs's TCR2 Therapeutics Inc. Common Stock position peaked at $8.41M in Q1 2021.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.